| Date | Phase | Anouncement | Biotech | Pharma | Product | Disease | Country | Other |
|---|---|---|---|---|---|---|---|---|
| 2010-09-08 | III | Launch | Genmab (Denmark) | GSK (UK) | Ofatumumab + bendamustine | indolent B-cell non-Hodgkin’s lymphoma | See details | |
| 2010-09-07 | I-II | Result | Immutep (France) | IMP321 (recombinant soluble LAG-3Ig fusion protein that binds to MHC class II with high avidity and mediates APC and then antigen-experienced memory CD8+ T cell activation) | metastatic breast cancer | France | See details | |
| 2010-09-06 | III | Result | Thrombogenics (Belgium) | microplasmin | Retinal disorders | Europe and North America | See details | |
| 2010-08-18 | III | Launch | Clavis Pharma (Norway) | Elacytarabine (lipid-conjugated derivative of cytarabine developed using Clavis' lipid vector technology) The has been granted orphan drug status for the treatment of acute myeloid leukemia in the US and EU. | acute myeloid leukemia | USA and Europe | See details | |
| 2010-08-11 | I-IIa | Launch | Algeta (Norway) | Alpharadin® (radium-223 chloride - first-in-class alpha-pharmaceutical) | Prostate cancer | USA (Memorial Sloan-Kettering Cancer Center in New York and up to nine other centers in the USA) | See details | |
| 2010-08-10 | II | Result | Genmab (Denmark) | Arzerra® (ofatumumab) | relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | See details | ||
| 2010-08-09 | III | Result | Genmab (Denmark) | GSK (UK) | Arzerra® (ofatumumab) | fludarabine and alemtuzumab refractory chronic lymphocytic leukemia | See details | |
| 2010-08-06 | I | Launch | Galapagos (Belgium) | GLPG0634 (JAK inhibitor) This orally-available, novel candidate drug is selective against Janus kinase (JAK) 1 and 2 targets discovered in collaboration with GSK. The product was formally part of their arthritis alliance. Galapagos re-acquired the rights to GLPG0634 from GSK for an undisclosed amount and will initiate clinical development of this candidate without any further involvement from GSK. | arthritis | Belgium | See details | |
| 2010-08-06 | II | Launch | Clavis Pharma (Norway) | CP-4126 (lipid-conjugated derivative of gemcitabine, developed using Clavis' lipid vector technology) | pancreatic cancer | See details | ||
| 2010-08-04 | I | Launch | Glycotope (Germany) | CetuGEX™ (GT-MAB 5.2-GEX) | Various solid cancers | Germany, Italy | See details | |
| 2010-08-02 | I | Launch | MorphoSys (Germany) | Novartis (Switzerland) | Undisclosed HuCAL-derived, fully human antibody | Ophtalmology area | See details | |
| 2010-07-23 | I | Launch | Genticel (France) | ProCervix® The vaccine is composed of two recombinant Adenylate Cyclase proteins (CyaA) in equal parts. | Prevention of cervical cancer in patients already infected with human papillomavirus (HPV) | Belgium | See details | |
| 2010-07-17 | II | Launch | BiondVax Pharmaceuticals (Israel) | multimeric-001 vaccine (universal influenza vaccine) | influenza | Israel | See details | |
| 2010-07-12 | I-IIa | Result | Biogen Idec (USA) Swedish Orphan Biovitrum (Sweden) | Long-acting recombinant factor IX Fc fusion protein (rFIXFc) | hemophilia B | See details | ||
| 2010-07-12 | II | Launch | Transgene (France) | TG4040 (MVA-HCV, MVA virus carrying and expressing non structural proteins (NS3, NS4 et NS5B) of the hepatitis C virus) | Hepatitis C | Europe, USA and Israel | See details |
